TFC Financial Management Has $10.25 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

TFC Financial Management reduced its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 57,815 shares of the company’s stock after selling 732 shares during the quarter. Johnson & Johnson makes up about 2.9% of TFC Financial Management’s portfolio, making the stock its 5th biggest holding. TFC Financial Management’s holdings in Johnson & Johnson were worth $10,247,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Family CFO Inc acquired a new position in Johnson & Johnson in the 4th quarter valued at $26,000. Steward Financial Group LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC raised its holdings in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $174.59 on Thursday. The stock has a market cap of $459.42 billion, a P/E ratio of 25.41, a price-to-earnings-growth ratio of 3.31 and a beta of 0.59. The company has a current ratio of 1.42, a quick ratio of 1.14 and a debt-to-equity ratio of 0.37. The stock’s 50-day moving average is $175.57 and its 200-day moving average is $174.49. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.48 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Raymond James lifted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Citigroup decreased their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Finally, Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.